Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Short Interest Update
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Short Interest Update
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT – Get Rating) was the target of a large drop in short interest in July. As of July 31st, there was short interest totalling 32,900 shares, a drop of 31.9% from the July 15th total of 48,300 shares. Based on an average trading volume of 49,200 shares, the short-interest ratio is currently 0.7 days.
奥品制药公司(纳斯达克代码:OPNT-GET Rating)是空头股数7月份大幅下跌的目标。截至7月31日,空头股数共有3.29万股,较7月15日的4.83万股下降了31.9%。以平均成交量49,200股计算,目前短息比率为0.7天。
Analyst Ratings Changes
分析师评级发生变化
Separately, TheStreet lowered Opiant Pharmaceuticals from a "c" rating to a "d+" rating in a research report on Tuesday, May 31st.
另外,华尔街在5月31日(星期二)的一份研究报告中将Opiant PharmPharmticals的评级从“c”下调至“d+”。
Insiders Place Their Bets
内部人士下注
In other news, Director Michael Sinclair sold 7,688 shares of the company's stock in a transaction on Monday, June 6th. The shares were sold at an average price of $12.94, for a total value of $99,482.72. Following the completion of the sale, the director now owns 41,532 shares in the company, valued at approximately $537,424.08. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Michael Sinclair sold 7,688 shares of the business's stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $12.94, for a total transaction of $99,482.72. Following the transaction, the director now directly owns 41,532 shares in the company, valued at $537,424.08. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Craig A. Collard acquired 4,037 shares of the firm's stock in a transaction on Monday, June 13th. The stock was purchased at an average price of $10.94 per share, with a total value of $44,164.78. Following the purchase, the director now owns 53,822 shares in the company, valued at approximately $588,812.68. The disclosure for this purchase can be found here. Insiders have sold 23,751 shares of company stock valued at $304,412 in the last three months. 25.15% of the stock is currently owned by insiders.
在其他新闻方面,董事迈克尔·辛克莱在6月6日星期一的一笔交易中出售了7688股该公司股票。这些股票的平均价格为12.94美元,总价值为99,482.72美元。出售完成后,董事现在拥有该公司41,532股,价值约537,424.08美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,通过这个超级链接可以访问该文件。在相关新闻中,董事迈克尔·辛克莱在一笔日期为6月6日(星期一)的交易中出售了该公司7688股股票。这些股票以12.94美元的平均价格出售,总成交金额为99,482.72美元。交易完成后,董事现在直接拥有该公司41,532股,价值537,424.08美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,可以通过美国证券交易委员会网站访问该文件。此外,克雷格·A·科拉德在6月13日(星期一)的一次交易中收购了4,037股董事股票。该股是以每股10.94美元的平均价格购买的,总价值为44,164.78美元。收购完成后,董事现在拥有该公司53,822股,价值约588,812.68美元。此次收购的披露信息可在此处找到。在过去的三个月里,内部人士已经出售了23,751股公司股票,价值304,412美元。25.15%的股份目前由内部人士持有。
Institutional Investors Weigh In On Opiant Pharmaceuticals
机构投资者看好奥品制药
Opiant Pharmaceuticals Stock Performance
Opiant制药公司股票表现
Shares of Opiant Pharmaceuticals stock traded up $0.90 on Friday, reaching $13.48. 31,822 shares of the company traded hands, compared to its average volume of 17,959. The company has a debt-to-equity ratio of 0.35, a current ratio of 8.72 and a quick ratio of 8.72. The firm has a market capitalization of $68.48 million, a PE ratio of -3.31 and a beta of 0.52. The company has a 50 day moving average of $11.52 and a 200 day moving average of $18.20. Opiant Pharmaceuticals has a 52 week low of $7.34 and a 52 week high of $37.71.
周五,Opiant PharmPharmticals的股价上涨了0.9美元,达到13.48美元。该公司31,822股易手,而其平均成交量为17,959股。该公司的债务权益比为0.35,流动比率为8.72,速动比率为8.72。该公司市值为6848万美元,市盈率为-3.31,贝塔系数为0.52。该公司的50日移动均线切入位在11.52美元,200日移动均线切入位在18.20美元。Opiant PharmPharmticals的52周低点为7.34美元,52周高点为37.71美元。
Opiant Pharmaceuticals (NASDAQ:OPNT – Get Rating) last released its earnings results on Tuesday, May 10th. The technology company reported ($2.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($1.68). Opiant Pharmaceuticals had a negative return on equity of 46.15% and a negative net margin of 51.18%. The firm had revenue of $4.47 million during the quarter, compared to analysts' expectations of $7.13 million. During the same period in the prior year, the business earned ($0.66) earnings per share. Equities analysts forecast that Opiant Pharmaceuticals will post -6.21 earnings per share for the current year.
奥品制药(纳斯达克代码:OPNT-GET Rating)最近一次公布财报是在5月10日(星期二)。这家科技公司公布的季度每股收益(EPS)为2.43美元,低于分析师普遍预期的0.75美元和1.68美元。Opiant制药公司的净资产回报率为负46.15%,净利润率为负51.18%。该公司本季度营收为447万美元,高于分析师预期的713万美元。去年同期,该业务实现每股收益(0.66美元)。股票分析师预测,Opiant PharmPharmticals本年度每股收益将达到6.21美元。
About Opiant Pharmaceuticals
关于Opiant制药公司
(Get Rating)
(获取评级)
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
Opiant PharmPharmticals,Inc.是一家专业制药公司,开发治疗成瘾和药物过量的药物。该公司提供纳尔坎鼻喷剂,一种逆转阿片类药物过量的治疗方法。其候选产品包括治疗阿片类药物过量逆转、酒精使用障碍、急性大麻类药物过量和阿片类药物使用障碍的药物。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Opiant Pharmaceuticals (OPNT)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免费获取StockNews.com关于Opiant制药的研究报告(OPNT)
- 值得关注的两场重要的零售股大战
- MarketBeat:回顾中的一周2012-8-8
- 什么是WallStreetBets,他们的目标是什么股票?
- 机构和分析师推动Jack in the Box走高
- 你能猜到哪个电动车股票打败了特斯拉吗?
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Opiant PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Opiant制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。